Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
Treatment for Acute myeloid leukemia
Typical Dosage: Varies by preparative regimen and stem cell source
Effectiveness
90%
Safety Score
20%
Clinical Trials
100
Participants
100K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
20
DangerousModerateSafe
Treatment Details
Dosage Range
Varies by preparative regimen and stem cell source
Time to Effect
6-12 months for full immune recovery
Treatment Duration
Initial hospitalization 1-2 months, intensive outpatient 6-12 months, lifetime follow-up
Evidence Quality
HIGHNumber Needed to Harm (NNH)
5(Treat 5 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$50,000
Monitoring:$500,000
Side Effect Mgmt:$150,000
Total Annual:$700,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$120,000/QALY
QALYs Gained
6
Outcome-Based Costs
Cost per Remission
$1,400,000
Comparison vs Intensive Chemotherapy
Cost Difference
+$500,000/year
More expensive
QALY Difference
+3.00 QALYs
Better outcomes
Dominance
No dominance
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Outcomes
for Acute myeloid leukemia
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
16 active trials recruiting for Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) in Acute myeloid leukemia
The Efficacy of Allo-HSCT in ND HR-CBF-AML
NCT06458244RECRUITING
90 participants
OBSERVATIONAL
Shanghai, China
Started: Sep 21, 2024
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
NCT06571825RECRUITINGPHASE4
118 participants
INTERVENTIONAL
Hangzhou, China
Started: Jul 17, 2024
A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia
NCT04822766ACTIVE NOT RECRUITINGNA
24 participants
INTERVENTIONAL
Paris, France
Started: Dec 31, 2021
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
NCT03314974RECRUITINGPHASE2
300 participants
INTERVENTIONAL
Minneapolis, United States
Started: Mar 30, 2018
Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML
NCT07500441RECRUITING
100 participants
OBSERVATIONAL
Beijing, China
Started: Mar 20, 2026
A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia
NCT06903702RECRUITINGPHASE2
100 participants
INTERVENTIONAL
Basking Ridge, United States +6 more
Started: Jun 4, 2025
MRD Response-adapted Allo-HSCT for Adverse-risk AML
NCT06301425RECRUITINGNA
178 participants
INTERVENTIONAL
Beijing, China
Started: May 24, 2024
RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT
NCT05858814RECRUITINGPHASE1, PHASE2
72 participants
INTERVENTIONAL
Hefei, China
Started: May 4, 2023
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
NCT05772273RECRUITINGNA
43 participants
INTERVENTIONAL
Suzhou, China
Started: Mar 15, 2023
Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT
NCT05682755RECRUITINGPHASE1, PHASE2
77 participants
INTERVENTIONAL
Chengdu, China
Started: Dec 22, 2022
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML
NCT06232694RECRUITINGNA
54 participants
INTERVENTIONAL
Nanjing, China
Started: Jan 1, 2024
CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia
NCT07201727NOT YET RECRUITINGEARLY_PHASE1
10 participants
INTERVENTIONAL
Started: Sep 30, 2025
Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT
NCT06765928NOT YET RECRUITINGPHASE2
73 participants
INTERVENTIONAL
Shanghai, China
Started: Jan 1, 2025
The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT
NCT07126782RECRUITINGEARLY_PHASE1
10 participants
INTERVENTIONAL
Beijing, China
Started: Jul 20, 2025
IFN-α in Relapse Prevention.
NCT07449286NOT YET RECRUITINGPHASE2
100 participants
INTERVENTIONAL
Beijing, China
Started: Mar 1, 2026
Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)
NCT07183878RECRUITINGNA
138 participants
INTERVENTIONAL
Hangzhou, China
Started: Aug 20, 2025
Completed Clinical Trials
1 completed trial for Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) in Acute myeloid leukemia
Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy
NCT02487069COMPLETEDNA
876 participants
INTERVENTIONAL
Guangzhou, China
Started: Jun 1, 2015
Showing 20 of 107 total trials